TOP TEN perturbations for 40076_at (Homo sapiens)

Organism: Homo sapiens
Gene: 40076_at
Selected probe(set): 201379_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 40076_at (201379_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-2.759612
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)

Relative Expression (log2-ratio):-2.278078
Number of Samples:2 / 5
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted).

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):2.1979322
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):2.0995388
Number of Samples:3 / 2
Experimental expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid.
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

colorectal cancer study 33 (carcinoma; colonic mucosa) / adjacent colon mucosa sample

Relative Expression (log2-ratio):2.0171747
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control adjacent colon mucosa sample
Adjacent colon mucosa sample obtained by laser capture microdissection (LCM) from patients with colorectal cancer.

expO kidney cancer study 1 (renal cell carcinoma, NOS; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):1.9923124
Number of Samples:5 / 2
Experimental expO kidney cancer study 1 (renal cell carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma (NOS).
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.

precursor-B-ALL study 2 (E2A-PBX1) / T-ALL study 2

Relative Expression (log2-ratio):1.9780931
Number of Samples:2 / 13
Experimental precursor-B-ALL study 2 (E2A-PBX1)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG).
Control T-ALL study 2
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Dutch Childhood Oncology Group (DCOG).

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):1.9426012
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

pancreatic islet study 3 (re-differentiated; PPRF; 2d) / normal pancreatic islet sample

Relative Expression (log2-ratio):1.9331408
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 2d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 2 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary) / expO kidney cancer study 1 (neoplasm, malignant; primary)

Relative Expression (log2-ratio):1.8167782
Number of Samples:22 / 2
Experimental expO kidney cancer study 1 (papillary adenocarcinoma, NOS; primary)
Primary tumor tissue samples obtained from the kidney of patients with papillary adenocarcinoma (NOS).
Control expO kidney cancer study 1 (neoplasm, malignant; primary)
Primary tumor tissue samples obtained from the kidney of patients with malignant neoplasm.